165 related articles for article (PubMed ID: 27302557)
1. Cost effectiveness of cancer treatment in Taiwan.
Hung MC; Lai WW; Chen HH; Lee JC; Lin YJ; Hsiao JR; Cheng YM; Shan YS; Su WC; Wang JD
J Formos Med Assoc; 2016 Aug; 115(8):609-18. PubMed ID: 27302557
[TBL] [Abstract][Full Text] [Related]
2. Cost per QALY (quality-adjusted life year) and lifetime cost of prolonged mechanical ventilation in Taiwan.
Hung MC; Lu HM; Chen L; Lin MS; Chen CR; Yu CJ; Wang JD
PLoS One; 2012; 7(9):e44043. PubMed ID: 22970160
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
[TBL] [Abstract][Full Text] [Related]
4. Estimating the lifelong health impact and financial burdens of different types of lung cancer.
Yang SC; Lai WW; Su WC; Wu SY; Chen HH; Wu YL; Hung MC; Wang JD
BMC Cancer; 2013 Dec; 13():579. PubMed ID: 24308346
[TBL] [Abstract][Full Text] [Related]
5. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.
Lang HC; Chen HW; Chiou TJ; Chan AL
J Med Econ; 2016 Oct; 19(10):923-7. PubMed ID: 27135256
[TBL] [Abstract][Full Text] [Related]
6. Estimation of quality-adjusted life expectancy in patients under prolonged mechanical ventilation.
Hung MC; Yan YH; Fan PS; Lin MS; Chen CR; Kuo LC; Yu CJ; Wang JD
Value Health; 2011; 14(2):347-53. PubMed ID: 21402303
[TBL] [Abstract][Full Text] [Related]
7. Impact of work-related cancers in Taiwan-Estimation with QALY (quality-adjusted life year) and healthcare costs.
Lee LJ; Lin CK; Hung MC; Wang JD
Prev Med Rep; 2016 Dec; 4():87-93. PubMed ID: 27413666
[TBL] [Abstract][Full Text] [Related]
8. Estimation of the financial burden to the National Health Insurance for patients with major cancers in Taiwan.
Chu PC; Hwang JS; Wang JD; Chang YY
J Formos Med Assoc; 2008 Jan; 107(1):54-63. PubMed ID: 18218578
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
13. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
16. Lifetime risks, expected years of life lost, and cost-per-life year of esophageal cancer in Taiwan.
Lai WW; Lin CN; Chang CC; Wang JD
Sci Rep; 2020 Feb; 10(1):3722. PubMed ID: 32111930
[TBL] [Abstract][Full Text] [Related]
17. Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan.
Lêng CH; Chou MH; Lin SH; Yang YK; Wang JD
Schizophr Res; 2016 Mar; 171(1-3):97-102. PubMed ID: 26811230
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
